Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsInterest & Investment IncomeNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) EBITDA (2020 - 2025)

Historic EBITDA for Roivant Sciences (ROIV) over the last 6 years, with Q4 2025 value amounting to -$339.2 million.

  • Roivant Sciences' EBITDA fell 2360.66% to -$339.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.2 billion, marking a year-over-year decrease of 12732.26%. This contributed to the annual value of -$1.0 billion for FY2025, which is 12231.01% down from last year.
  • Latest data reveals that Roivant Sciences reported EBITDA of -$339.2 million as of Q4 2025, which was down 2360.66% from -$306.2 million recorded in Q3 2025.
  • In the past 5 years, Roivant Sciences' EBITDA registered a high of $5.1 billion during Q4 2023, and its lowest value of -$684.4 million during Q3 2021.
  • Moreover, its 5-year median value for EBITDA was -$280.8 million (2022), whereas its average is $64.2 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 33722.03% in 2021, then soared by 145619.33% in 2023.
  • Over the past 5 years, Roivant Sciences' EBITDA (Quarter) stood at -$246.0 million in 2021, then crashed by 53.68% to -$378.1 million in 2022, then surged by 1456.19% to $5.1 billion in 2023, then tumbled by 105.35% to -$274.4 million in 2024, then decreased by 23.61% to -$339.2 million in 2025.
  • Its EBITDA was -$339.2 million in Q4 2025, compared to -$306.2 million in Q3 2025 and -$284.9 million in Q2 2025.